Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ER alpha-targeting chimeric protein degrader AC682

An orally bioavailable, selective estrogen receptor (ER) alpha-targeted chimeric protein degrader, with potential antineoplastic activity. Upon oral administration, ER alpha-targeting chimeric protein degrader AC682 targets ER alpha wild-type and mutants and induces the degradation of ER alpha proteins. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation. AC682 is able to cross the blood-brain barrier (BBB).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ER degrader AC0682
ER-alpha protein degrader AC0682
ERa degrader AC0682
estrogen receptor alpha-targeting chimeric protein degrader AC0682
Code name:AC 0682
AC 682
AC-0682
AC-682
AC0682
AC682
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search